

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re *Inter Partes* Review of:                    )  
U.S. Patent No. 7,297,703                        )  
Issued: Nov. 20, 2007                            )  
Application No.: 11/020,860                    )  
Filing Date: Dec. 23, 2004                    )

For: **Macrolides**

**FILED VIA PRPS**

**PETITION FOR *INTER PARTES* REVIEW  
OF U.S. PATENT NO. 7,297,703**

**Table of Contents**

I. Introduction..... 1

II. Requirements for Petition for *Inter Partes* Review..... 1

    A. Grounds for Standing (37 C.F.R. § 42.104(a)) ..... 1

    B. Notice of Lead and Backup Counsel and Service Information..... 1

    C. Notice of Real-Parties-in-Interest (37 C.F.R. § 42.8(b)(1))..... 2

    D. Notice of Related Matters (37 C.F.R. § 42.8(b)(2))..... 3

    E. Fee for *Inter Partes* Review ..... 3

    F. Proof of Service..... 3

III. Identification of Claims Being Challenged (§ 42.104(B))..... 3

IV. Description of The Purported Invention..... 4

V. Background Knowledge of a POSA of the '703 Patent ..... 5

    A. Solid Mixtures, Including Solid Dispersions, Were Well-Known in the Art..... 5

    B. Microemulsions Were Well-Known in the Art..... 7

    C. Poly-ene Macrolides, Including Rapamycin and its Derivative 40-O-(2-hydroxy)ethyl-rapamycin, Were Well-Known in the Art..... 7

    D. Poly-ene Macrolides, Including Rapamycin and the Rapamycin Derivative 40-O-(2-hydroxy)ethyl Rapamycin, Were Well-Known to be Unstable under Normal Conditions and Were Routinely Stabilized by Mixing with Antioxidants, Including Vitamin E, Vitamin C, and 2,6-di-*tert*-butyl-4-methylphenol (BHT) ..... 8

    E. Solid Mixtures of Poly-ene Macrolides, Including Rapamycin and its Derivative 40-O-(2-hydroxy)ethyl-rapamycin, Were Routine and Included Pharmaceutical Compositions Containing Pharmaceutically Acceptable Carriers or Diluents ..... 11

VI. The Person of Ordinary Skill in the Art ..... 11

VII. The Invalidating Prior Art Relied Upon..... 12

    A. Guitard (Ex. 1004)..... 12

    B. Fricker (Ex. 1005) ..... 14

C.	Eastlick (Ex. 1006).....	16
VIII.	Motivation to Combine the Prior Art References.....	18
A.	Motivation to Combine Fricker with Eastlick.....	19
B.	Reasonable Expectation of Success in Combining Fricker with Eastlick .....	23
IX.	Claim Construction.....	24
A.	“solid mixture” .....	25
B.	“catalytic amount” .....	26
C.	“admixed with” .....	27
X.	Precise Reasons For The Relief Requested.....	29
F.	Ground 1: Claims 1-3, 6-9, and 11 are Invalid under 35 U.S.C. § 102 on the Ground That They are Anticipated by Guitard .....	31
G.	Ground 2: Claims 1-3, 6-9, and 11 are invalid under 35 U.S.C. § 103 on the Ground That They are Rendered Obvious by Eastlick in view of Fricker .....	42
XI.	Conclusion .....	60

**Exhibit List**

- 1001 U.S. Patent No. 7,297,703 (“the ’703 Patent”)
- 1002 Declaration of Eric J. Benjamin, Ph.D. in Support of Petition for *Inter Partes* Review of U.S. Patent No. 7,297,703
- 1003 Curriculum Vitae of Eric J. Benjamin, Ph.D.
- 1004 International Publication No. WO 97/03654, “Pharmaceutical Compositions,” filed July 12, 1996, published Feb. 6, 1997 (“Guitard”)
- 1005 Canadian Application No. 2,124,259, “Galenic Formulations,” filed May 25, 1994, published Nov. 28, 1994 (“Fricker”)
- 1006 European Publication No. 0329460, “Stabilised macrolide compositions,” filed Feb. 17, 1989, published Aug. 23, 1989 (“Eastlick”)
- 1007 Tamio Mizutani *et al.*, *Isotope Effects on the Metabolism and Pulmonary Toxicity of Butylated Hydroxytoluene in Mice by Deuteration of the 4-Methyl Group*, 69 TOXICOLOGY & APPLIED PHARMACOLOGY 283 (1983)
- 1008 Anjni Koul *et al.*, *Chapter III: Extraction of Membrane Lipids*, in MANUAL ON MEMBRANE LIPIDS 37 (1996)
- 1009 J.S. Hogan *et al.*, *Bovine Neutrophil Responses to Parenteral Vitamin E*, 75 J. DAIRY SCI. 399 (2001)
- 1010 Rita Carini *et al.*, *Comparative evaluation of the antioxidant activity of  $\alpha$ -tocopherol,  $\alpha$ -tocopherol polyethylene glycol 1000 succinate and  $\alpha$ -tocopherol succinate in isolated hepatocytes and liver microsomal suspensions*, 39 BIOCHEMICAL PHARMACOLOGY 1597 (1990)
- 1011 Helmut Sapper *et al.*, *The thermotropic phase behavior of ascorbyl palmitate: an infrared spectroscopic study*, 59 CAN. J. CHEMISTRY 2543 (1981)
- 1012 Excerpts from *Grant & Hackh’s Chemical Dictionary* (5th ed. 1987)
- 1013 Excerpt from *A Dictionary of Pharmaceutical Science* (1882)
- 1014 Excerpts from *Webster’s New Collegiate Dictionary* (9th ed. 1984)

Petition for *Inter Partes* Review of USP 7,297,703

1015 *Dictionary.com*, accessed May 26, 2015, available at  
<http://dictionary.reference.com/browse/admix?s=t>

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.